Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proceeds from the financing will primarily be used to complete the preclinical testing of SR-01, Seraxis’ lead cell therapy treatment for insulin-dependent diabetes and initiate first-in-human clinical trials.
Lead Product(s): SR-01
Therapeutic Area: Endocrinology Product Name: SR-01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 09, 2021